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The Advancing Clinical Impact of
Molecular Imaging in CVD
Eric A. Osborn, MD, PHD,*y Farouc A. Jaffer, MD, PHDyz
Boston, MassachusettsMolecular imaging seeks to unravel critical molecular and cellular events in living subjects by providing
complementary biological information to current structural clinical imaging modalities. In recent years,
molecular imaging efforts have marched forward into the clinical cardiovascular arena, and are now
actively illuminating new biology in a broad range of conditions, including atherosclerosis, myocardial
infarction, thrombosis, vasculitis, aneurysm, cardiomyopathy, and valvular disease. Development of
novel molecular imaging reporters is occurring for many clinical cardiovascular imaging modalities
(positron emission tomography, single-photon emission computed tomography, magnetic resonance
imaging), as well as in translational platforms such as intravascular ﬂuorescence imaging. The ability
to image, track, and quantify molecular biomarkers in organs not routinely amenable to biopsy (e.g.,
the heart and vasculature) open new clinical opportunities to tailor therapeutics based on a
cardiovascular disease molecular proﬁle. In addition, molecular imaging is playing an increasing role
in atherosclerosis drug development in phase II clinical trials. Here, we present state-of-the-art clinical
cardiovascular molecular imaging strategies, and explore promising translational approaches
positioned for clinical testing in the near term. (J Am Coll Cardiol Img 2013;6:1327–41) ª 2013 by
the American College of Cardiology FoundationMolecular imaging aims to delineate important
biological disease processes that are invisible
to traditional structural diagnostic imaging
modalities. Clinical cardiovascular molecular
imaging efforts are increasingly providing
new molecular and cellular insights into the in
vivo biology of various cardiovascular diseases,
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A B B R E V I A T I O N S
A N D A C R O N YM S
158Gd-ESMA =
gadolinium-labeled
elastin-speciﬁc magnetic
resonance contrast agent
AS = aortic stenosis
AT1R = angiotensin II type
1 receptor
CAC = coronary artery
calcium
CEA = carotid
endarterectomy
CMR = cardiac magnetic
resonance
CT = computed
tomography
DVT = deep vein
thrombosis
FDA = Food and Drug
Administration
FDG = 18F-
ﬂuorodeoxyglucose
hsCRP = high-sensitivity
C-reactive protein
ICG = indocyanine green
LDL = low-density
lipoprotein
LV = left ventricle/
ventricular
MI = myocardial infarction
MMP = matrix
metalloproteinase
MRI = magnetic
resonance imaging
NaF = 18F-sodium ﬂuoride
NIRF = near-infrared
ﬂuorescence
OFDI = optical frequency
domain imaging
OTW = over-the-wire
PC = perfusion catheter
PET = positron emission
tomography
RAAS = renin-
angiotensin-aldosterone
system
SUV = standardized
uptake value
TBR = target-to-
background ratio
USPIO = ultrasmall
superparamagnetic
particles of iron oxide
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1328and provided several recommendations for fostering
further development of the ﬁeld (1). In this
review, we highlight recent advances
in cardiovascular molecular imaging, encom-
passing studies published in 2011 and 2012,
focusing on clinical applications and impor-
tant translational pre-clinical advances. Key
questions for the ﬁeld include: 1) will molec-
ular imaging readouts translate into improved
clinical risk stratiﬁcation? 2) Can molecular
imaging predict the success or failure of new
pharmacotherapies in early stagesdto help
streamline drug development?
Atherosclerosis
Molecular imaging aims to identify and guide
treatment of vulnerable atherosclerotic plaques
at high risk of rupture and subsequent
thrombosis. Putative at-risk lesions display
pathological features such as inﬂammation,
thrombosis, neovessel formation, apoptosis,
and hemorrhage, several of which are well
suited to detection with molecular imaging
agents (Table 1). Although noninvasive
positron emission tomography (PET)-based
metabolism/inﬂammation plaque imaging
with 18F-ﬂuorodeoxyglucose (FDG) domi-
nates the current clinical landscape, emerging
agents such as 18F-sodium ﬂuoride (NaF) for
PET and new applications of magnetic reso-
nance imaging (MRI)-detectable ultrasmall
superparamagnetic particles of iron oxide
(USPIO), among other innovations, are being
explored. An overarching question that is
being addressed is: will molecular imaging
readouts provide additional risk prediction
beyond clinical risk factor scores, blood bio-
markers, and anatomic imaging?
Carotid plaque FDG PET imaging. FDG is a
radiolabeled glucose analog that concentrates in
metabolically active cells, and can be detected
by PET imaging. In atherosclerosis, FDG
correlates with macrophage inﬁltration, as well
as with plaque hypoxia, and overall serves as a
surrogate marker of plaque inﬂammation.
Although FDG PET imaging of plaque
inﬂammation is generally restricted to larger
arterial beds, such as the carotid arteries
and aorta, efforts to image the coronary arteries
are emerging. Due to its widespread clinical
availability, FDG-based PET/computed to-
mography (CT) molecular imaging studieshave dominated the atherosclerosis landscape.CLINICAL ASSOCIATIONS OF CAROTID PLAQUE FDG
SIGNAL ELEVATION WITH CARDIOVASCULAR RISK
FACTORS. Factors associated with carotid FDG
activity were assessed in a cross-sectional study of 82
subjects with stable coronary artery disease (2), of
which 95% were taking chronic statin therapy
and 38% had diabetes. Quantitative carotid FDG
uptake was assessed by multiple metrics including
maximum whole-vessel target-to-background ratios
(TBRs) and standardized uptake value (SUV). The
SUV was determined by measuring the local arte-
rial FDG activity corrected for the injected FDG
dose, and body weight or body surface area. How-
ever, because the target artery often contains plaque
and luminal FDG-positive blood, an attempt to
correct for residual background blood signal can be
made by dividing the plaque artery SUV by the
venous blood SUV, to generate a TBR value. Prior
work from Rudd et al. (3) have shown that the mean
and maximumTBRs are reproducible and suitable for
atherosclerosis drug trials, although other correction
methods, for example, plaque artery SUV minus
venous SUV, might also be useful. In the current
study, artery FDG SUVs and TBRs were correlated
with traditional cardiovascular risk factors through
multivariate linear regression analysis. The strongest
predictors of carotid FDG uptake were obesity (body
mass index$30 kg/m2) and age>65 years (both p#
0.01), followed by male sex and a history of hyper-
tension or smoking (all p # 0.05). Furthermore, the
number of metabolic syndrome features present
incrementally increased with carotid FDG activity.
Interestingly, the presence of diabetes alone was not
predictive in this study, although a subsequent
analysis of 43 non–insulin-dependent diabetic pa-
tients by the same investigators demonstrated a sig-
niﬁcant association between fasting glucose and
carotid FDGuptake, after correction for the pre-scan
blood glucose (4). The overall ﬁndings strengthen
the likelihood that FDG-PET will identify high-
risk plaques and patients. However, outcome
studies will be needed to determine whether FDG
plaque assessment improves risk prediction beyond
risk factors.
Another coronary artery disease equivalent, pe-
ripheral arterial disease, did not show signiﬁcant
correlation between FDG uptake and immunohis-
tological macrophage content in femoral arterial
plaque samples obtained from 21 patients who un-
derwent PET imaging within 2 weeks of catheter-
based directional atherectomy (5). However, it is
possible that these ﬁndings were limited by the
sample collection method that precluded accurate
FDG PET/CT coregistration.
Table 1. Clinically Targeted Molecular Imaging Agents (Partial List)
Agent Modality Primary Target Application
Clinically
Tested
FDG PET Glucose transporter-1, hexokinase Atherosclerosis, aneurysm, vasculitis
(metabolism)
Yes
NaF PET Hydroxyapatite Atherosclerosis (calciﬁcation) Yes
11C-acetate PET Fatty acid synthetase Atherosclerosis (fatty acids) Yes
[11C]-(R)-PK11195 PET Benzodiazepine receptor/macrophages Vasculitis (inﬂammation) Yes
11C-KR31173 PET Angiotensin II type I receptor Myocardial infarction, cardiomyopathy
(remodeling)
Yes
18F-EF5 PET Hypoxic cells Atherosclerosis (inﬂammation) Yes
64Cu-DTPA-ProT PET Staphylocoagulase Endocarditis (vegetations) No
99mTc-annexin V SPECT Annexin/macrophages Myocardial infarction, cardiomyopathy
(apoptosis)
Yes
99mTc-RIP (radiolabeled RGD
imaging peptide)
SPECT avb3 Integrins Myocardial infarction (ﬁbrosis) Yes
99mTc-exametazime leukocytes SPECT White blood cells Transplant (inﬂammation) Yes
111In-RP782 SPECT Matrix metalloproteinases Atherosclerosis (inﬂammation) No
99mTc-RP805 SPECT Matrix metalloproteinases Atherosclerosis (inﬂammation) No
99mTc-fucoidin SPECT P-selectin Atherosclerosis, thrombosis, endocarditis
(inﬂammation)
No
99mTc-NC100692 SPECT avb3 Integrins Vascular injury (inﬂammation) No
N1177 CT Macrophages Atherosclerosis (inﬂammation) No
P-selectin microbubbles Ultrasound P-selectin Vascular injury (inﬂammation) No
Supravist (SHU 555 C) MRI Macrophages Atherosclerosis (inﬂammation) Yes
SPIO/USPIO MRI Macrophages Atherosclerosis (inﬂammation) Yes
EP-2104R MRI Fibrin Thrombosis (coagulation) Yes
P947 MRI Matrix metalloproteinases Atherosclerosis (inﬂammation) No
FeCo/graphite nanocrystals MRI Macrophages Atherosclerosis (inﬂammation) No
158Gd-ESMA MRI Elastin Atherosclerosis (plaque burden) No
BMS-753951 MRI Elastin Atherosclerosis (plaque burden) No
CNA-35 MRI Collagen Aneurysm (extracellular matrix) No
Gd-TO MRI DNA Myocardial infarction (necrosis) No
VS-580H MRI Macrophages Transplant (inﬂammation) No
SPIO-labeled EPC MRI Endothelial progenitor cells Transplant (cell tracking) No
Human ferritin cages MRI, NIRF Macrophages Atherosclerosis (inﬂammation) No
avb3-Targeted nanoparticles MRI, NIRF avb3 Integrins Atherosclerosis (neovessels) No
18F-CLIO MRI, NIRF Macrophages Atherosclerosis, aneurysm (inﬂammation) No
ICG NIRF Lipids/macrophages Atherosclerosis (inﬂammation) Yes
ProSense NIRF Cysteine proteases Atherosclerosis (inﬂammation) No
MMPsense NIRF Matrix metalloproteinases Atherosclerosis (inﬂammation) No
FTP11-Cy7 NIRF Fibrin Thrombosis (coagulation) No
158Gd-ESMA ¼ gadolinium-labeled elastin-speciﬁc magnetic resonance contrast agent; CT ¼ computed tomography; EPC ¼ endothelial progenitor cell(s); FDG ¼
18F-ﬂuorodeoxyglucose; ICG ¼ indocyanine green; MRI ¼ magnetic resonance imaging; NaF ¼ 18F-sodium ﬂuoride; NIRF ¼ near-infrared ﬂuorescence; PET ¼ positron emission
tomography; RGD ¼ arginine-glycine-aspartic acid; SPECT ¼ single-photon emission computed tomography; SPIO ¼ superparamagnetic iron oxide; USPIO ¼ ultrasmall super-
paramagnetic iron oxide.
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1329ASSOCIATIONS BETWEEN CAROTID PLAQUE FDG
UPTAKE AND HIGH-RISK PLAQUE MORPHOLOGY.
Inﬂammation, expansive remodeling, lipid-rich
necrotic core, and ulceration are high-risk featuresunderlying plaque rupture. Associations between
FDG inﬂammation and CT high-risk plaque
morphological characteristics were examined in 34
patients with carotid stenosis (6). Compared with
Figure 1.
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1330plaques without high-risk features, those demon-
strating CT-positive remodeling, luminal irregu-
larity (ulceration), or low attenuation (lipid) had
greater FDG PET activity (TBR: 2.2 any marker
vs. 1.7 no marker, p < 0.001). In addition, the
carotid FDG signal increased as a function of the
number of high-risk features present (p < 0.001).
Immunohistochemistry of carotid endarterectomy
(CEA) specimens demonstrated greater macrophage
content in high-FDG plaques that tracked with
more high-risk morphology features (p < 0.001).
Future clinical atherosclerosis imaging risk stratiﬁ-
cation strategies are likely to be strengthened by
combining molecular imaging data with detailed
structural information on plaque morphology. These
data extend the potential of FDG-PET/CT to
identify high-risk carotid plaques. However, in the
next years, FDG inﬂammation imaging will need to
show utility beyond anatomic imaging to become
routinely clinically adopted.
CAROTID PLAQUE FDG AND PERIODONTAL
INFLAMMATION. Can the teeth serve as a window
to the health of the arteries? Severe periodontal
disease is associated with adverse cardiovascular
outcomes. To further understand the association
between periodontal disease and atherosclerosis, 112Periodontal FDG-PET
mission tomography (PET) (top, right) and PET/computed tomography
(top, left) images reveal high 18F-ﬂuorodeoxyglucose (FDG) uptake in
al tissues (boxes indicatemeasurement regions).Quantitative target-to-
d ratio (TBR) of periodontal FDG activity signiﬁcantly correlated with
G uptake. Reproduced, with permission, from Fifer et al. (7).patients underwent jaw and large-artery FDG im-
aging (7). The periodontal FDG signal correlated
well with the carotid artery signal (r ¼ 0.64, p <
0.001), and also to a lesser extent with aorta signal
(r ¼ 0.38, p ¼ 0.029) (Fig. 1). In a subset of 16
patients who subsequently underwent CEA, FDG
signals correlated well with plaque macrophages
(r ¼ 0.81, p < 0.001), further supporting FDG as a
reporter of local tissue macrophage inﬁltration. This
insight may motivate strategies to further under-
stand whether periodontal disease could actually
drive atherosclerosis (via the generation of a sys-
temic inﬂammatory response) or vice versa, or
whether preceding systemic inﬂammation drives
both periodontal disease and atherosclerosis. This
study could also help reinvigorate efforts to screen
patients with poor periodontal health for cardio-
vascular disease.
FDG PLAQUE UPTAKE IN A JUPITER-TYPE PRIMARY
PREVENTION POPULATION. Mechanisms underly-
ing the beneﬁts of statins in patients with “normal”
low-density lipoprotein (LDL) levels remain un-
known. Yoo et al. (8) evaluated carotid FDG ac-
tivity in 120 apparently healthy individuals stratiﬁed
according to baseline high-sensitivity C-reactive
protein (hsCRP) and LDL values. The study design
was similar to the JUPITER (Justiﬁcation for the
Use of Statins in Primary Prevention: An Inter-
vention Trial Evaluating Rosuvastatin) trial, which
demonstrated a rosuvastatin-mediated reduction in
cardiovascular events and all-cause mortality in those
with “normal” LDL levels <130 mg/dl, but with
elevated systemic inﬂammation deﬁned by hsCRP
$2.0 mg/l. Using these same cutoff strata, subjects
with hsCRP $2.0 mg/l and low LDL <130 mg/dl
had greater carotid FDG signals than those with low
hsCRP/low LDL, or low hsCRP/high LDL
(maximum TBR: 1.29  0.13, 1.12  0.10, and
1.16  0.15, respectively; p < 0.01). Notably, there
were no differences in carotid ultrasound intima-
media thickness among these groups. This exciting
study provides new insights in that plaques can be
inﬂamed despite a “normal” LDL level. Future
studies need to determine whether local FDG plaque
inﬂammation detection offers superior risk predic-
tion beyond risk factors and the blood hsCRP level,
a simpler and much less costly test.
ASSESSMENT OF ANTI-INFLAMMATORY EFFECTS OF
ANTIDIABETES PHARMACOTHERAPY. Reduction of
atheroma inﬂammation is hypothesized as a strategy
to stabilize vulnerable plaques, and is being formally
tested in large clinical trials using agents such as
methotrexate (CIRT [Cardiovascular Inﬂammation
Figure 2. Effect of Pioglitazone and Glimepiride on Atherosclerotic
Plaque FDG Uptake
FDG PET/CT images from representative patients treated at baseline (left) or
following 4 months treatment (right) with pioglitazone or glimepiride. Arrows
indicate an area of reduced FDG uptake in the pioglitazone arm. Reproduced,
with permission, from Mizoguchiet al. (9). Abbreviations as in Figure 1.
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1331Reduction Trial]) and canakinumab (CANTOS
[Canakinumab Anti-inﬂammatory Thrombosis
Outcomes Study]). Identifying speciﬁc Food and
Drug Administration (FDA)-approved agents that
exhibit plaque-speciﬁc anti-inﬂammatory effects,
particularly in higher-risk diabetic patients, could be
of considerable importance. To this end, Mizoguchi
et al. (9) compared the anti-inﬂammatory properties
of 2 antidiabetic agents, pioglitazone (insulin sensi-
tizing) and glimepiride (insulin secreting), in a serial
FDG imaging trial of 56 randomized diabetic pa-
tients. Compared with pre-randomization baseline
FDG imaging, the pioglitazone-treated group
demonstrated signiﬁcantly greater suppression of
FDG carotid and aortic plaque inﬂammation
compared with the glimepiride group (pioglitazone
DTBR:0.14, p < 0.01; glimepiride DTBR:þ0.06,
p ¼ NS) (Fig. 2). Notably, each group showed
similar reductions in fasting plasma glucose and he-
moglobin A1c levels. This study extends prior pre-
clinical imaging evidence of decreased inﬂammation
observed with pioglitazone (10,11) and may underlie
the favorable clinical and ultrasound imaging results
observed in the PROactive (Prospective Pioglitazone
Clinical Trial in Macrovascular Events), CHICAGO
(Carotid Intima-Media Thickness in Atherosclerosis
Using Pioglitazone), and PERISCOPE (Pioglitazone
Effect on Regression of Intravascular Sonographic
CoronaryObstructionProspectiveEvaluation) clinical
trials.
ANTI-INFLAMMATORY EFFECT OF NEW LIPID-MODI-
FYING AND ANTI-INFLAMMATORY THERAPEUTICS.
Developing new pharmacotherapies for cardiovascu-
lar disease is of paramount importance but a time-
consuming, costly endeavor. Agents that increase
high-density lipoprotein levels appeared initially
attractive, but recent experience with the cholester-
ylesterase transfer protein (CETP) inhibitor torce-
trapib was associated with increased mortality
attributed to off-target effects. Dalcetrapib, a new
CETP inhibitor, was tested in the phase
2b, randomized, double-blind, placebo-controlled
dal-PLAQUE (A Study of the Effect of Dalcetrapib
on Atherosclerotic Plaque in Patients with Coronary
Heart Disease) trial that included atheroma char-
acterization endpoints by serial carotid MRI and
FDG PET imaging (12). At 6 months, dalcetrapib
increased high-density lipoprotein levels by 34%.
PET imaging demonstrated a modest nonsigniﬁcant
trend towards decreased carotid FDG activity
compared with controls (7.3%TBR reduction, 90%
conﬁdence interval: 13.5 to 0.8). Serial MRI,
however, showed a relative 4.0-mm2 reduction in totalcarotid wall area at 24months comparedwith baseline
(dalcetrapib vs. control, p¼ 0.04). In comparisonwith
torcetrapib, dalcetrapib demonstrated a good safety
proﬁle without enhancing plaque progression or
inﬂammation. However, despite these potentially
encouraging ﬁndings, the dalcetrapib phase 3 study
dal-OUTCOMES (A Study of Dalcetrapib in Stable
Coronary Heart Disease Patients with Recent Acute
Coronary Syndrome) was recently halted for futility.
Therefore, the ﬁeld of surrogate atherosclerosis im-
aging is still in need of a predictive champion. FDG
PET has proven successful in showing statin-based
reductions in plaque inﬂammationdbut statins
already were established with hard endpoints before
such imaging trials. Perhaps both carotid imaging
endpoints togetherdreduction of inﬂammation by
FDG and reduction of plaque volume by MRIdwill
be more predictive of drug success, at least in reducing
cerebrovascular events. Whether a non-coronary
artery–based molecular imaging method can accu-
rately predict coronary events also remains to be
determined.
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modulation, is also a promising emerging thera-
peutic target. The “inﬂammatory hypothesis” will be
tested clinically in clinical trials of low-dose meth-
otrexate (CIRT trial), the interleukin-1b inhibitor
canakinumab (CANTOS trial), and of other novel
anti-inﬂammatory therapeutics. One new agent,
losmapimod, which inhibits p38 mitogen–activated
protein kinase intracellular inﬂammation pathways,
was tested in 99 patients already on statin therapy
randomized 1:1:1 to once or twice daily 7.5-mg
losmapimod or placebo. Carotid and aorta inﬂam-
mation was imaged with FDG PET/CT at baseline
and 84 days later (13). Although averaging all
analyzable segments demonstrated no signiﬁcant
relationships, secondary analysis restricted to seg-
ments with high FDG signal at baseline (TBR$1.6)
showed mild, but signiﬁcant, FDG reduction in the
once and twice daily losmapimod groups compared
with placebo (both DTBR 0.10, p < 0.02). In
support, losmapimod reduced serum inﬂammatory
biomarkers (hsCRP, interleukin-8, matrix metal-
loproteinase 9 [MMP-9], monocyte chemotactic
protein-1) and visceral fat FDG uptake, indicating a
systemic anti-inﬂammatory effect. We eagerly await
outcome trials to understand whether these FDG
PET imaging ﬁndings will have predicted the suc-
cess of losmapimod on clinical endpoints.
LIMITATIONS OF FDG PET IMAGING OF INFLAMMA-
TION. Although linked to inﬂammation, the precise
mechanisms underlying FDG uptake in atheroma
are incompletely deﬁned. In an elegant set of ex-
periments, Folco et al. (14) demonstrated that
hypoxia mediates cellular FDG uptake in vitro.
Cultured human cells in conditions similar to those
experienced in atheroma demonstrated that hypoxia,
but not proinﬂammatory cytokines, augmented
macrophage glucose uptake. Furthermore, statins
attenuated the hypoxia-induced macrophage glucose
metabolism, whereas inﬂammatory cytokines up-
regulated glucose utilization in other cells, such as
smooth muscle cells and endothelial cells. There-
fore, mechanisms governing FDG uptake in vivo
may be more complex than previously realizedd
including inﬂammatory cells, other metabolically
active cells, and hypoxia.
Sodium 18F-ﬂuoride PET imaging of active plaque
calciﬁcation. Calciﬁcation is a cardinal process in
atherosclerosis, and bulk calciﬁcation is associated
with increased clinical risk when detected byCTor x-
ray. A promising plaque calciﬁcation-targeted PET
imaging agent is NaF, a marker of active minerali-
zation that has favorable pharmacokinetics andminimal nonspeciﬁc soft tissue uptake, and has been
clinically used to detect bone metastases. Derlin et al.
(15) examined NaF PET uptake in the common
carotid arteries of 269 asymptomatic cancer patients
undergoing PET/CT. Approximately 35% of pa-
tients demonstrated uptake of NaF in the carotid
artery. NaF signiﬁcantly correlated with the degree of
atherosclerotic calciﬁcation onCT imaging (r¼ 0.85,
p < 0.0001), although conversely, not all CT-
identiﬁed calciﬁcations demonstrated NaF PET
signal. NaF activity also associated with traditional
cardiovascular risk factors such as hypertension,
hyperlipidemia, age, and male sex. NaF is therefore a
new player in atherosclerosis PET imaging, and of-
fers new insights into atheroma progression com-
plementary to FDG PET, as discussed next.
COMPARISON OF FDG AND NAF SIGNALS IN
CAROTID PLAQUES. To further assess the differen-
tial topography of plaque metabolism and mineral-
ization in atherosclerosis, Derlin et al. (16)
retrospectively reviewed 45 PET/CT studies in
oncology patients who underwent both FDG and
NaF PET scans within a 6-month period. Most
subjects demonstrated focal carotid and aortic
vascular FDG uptake. However, calciﬁed lesions
associated preferentially with NaF rather than FDG
(77% vs. 15%, respectively). Notably, the overlap
between NaF and FDG signals were minimal,
occurring in only 6.5% of patients, again high-
lighting the spatial uniqueness of inﬂammation and
mineralization in atherosclerosis. This ﬁnding
further supports that bulk calciﬁcation may repre-
sent a “burnt out” end stage of atherosclerosis.
CORONARY IMAGING. In a remarkable advance,
NaF PET also enabled the noninvasive detection of
plaque mineralization in human coronary arteries
(17). In a study of 119 subjects with or without
calciﬁc aortic stenosis, NaF uptake was signiﬁcantly
associated with patients with angina, prior cardio-
vascular events, and traditional risk factors. NaF
PET was found to correlate with the CT coronary
artery calcium (CAC) score (r ¼ 0.652, p < 0.001).
Interestingly, a subset of patients with high CAC
scores >1,000 had no detectable NaF activity,
potentially indicating more stable, end-stage calci-
ﬁed plaques (Fig. 3). Yet this is potentially a chal-
lenge to understand NaF’s role in risk prediction,
because clinical CAC scores of >1,000 are associ-
ated with a markedly elevated cardiovascular risk. It
is likely that NaF is detecting earlier-stage calciﬁed
lesions with ongoing mineralization.
In an NaF versus FDG comparison study in the
same patients, FDG was not associated with
Figure 3. Coronary Artery NaF PET/CT Imaging
(A) A control group patient with absent coronary artery calcium and no cor-
onary 18F-sodium ﬂuoride (NaF) PET activity. Note the signiﬁcant vertebral
body NaF uptake. (B) Despite extensive left anterior descending coronary ar-
tery (LAD) calciﬁcation, coronary NaF signal is not present in this subject.
(C and D) Examples of patients with signiﬁcant NaF PET activity and CT cor-
onary calciﬁcation in the proximal and mid-LAD. (E) Heightened NaF coronary
PET uptake in the culprit proximal right coronary artery (RCA) of a patient after
recent inferior non–ST-segment elevation myocardial infarction. Note the
absence of LAD NaF PET signal. (F) Coronary angiography in the patient from
(E) demonstrated an ulcerated, thrombotic proximal RCA lesion. Reproduced,
with permission, from Dweck et al. (17).
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1333coronary atherosclerosis, likely due to strong back-
ground myocardial FDG uptake. Overall, NaF may
allow identiﬁcation of plaque calcium deposition in
remodeling atheromasdpotentially in the coronary
bed, a major advance for noninvasive molecular
imaging. The key question is whether NaF uptake
will predict cardiovascular events independently
beyond risk factors and the CACda question that
is critical for every coronary atherosclerosis molec-
ular imaging approach.
CAROTID PLAQUE INFLAMMATION IMAGING VIA
NEW MACROPHAGE-TARGETED AGENTS. A rela-
tively new PET agent, 11C-PK11195, targets
activated macrophages by selectively interacting
with the macrophage translocator protein (TSPO,
formerly known as the peripheral benzodiazepine
receptor). 11C-PK11195 PET/CT was performed
in 32 patients with >50% carotid stenosis (18).
In the 9 symptomatic patients with recent ipsi-
lateral stroke or transient ischemic attack, the
11C-PK11195 plaque signal was greater compared
with subjects with asymptomatic stenosis (TBR:
1.06  0.20 vs. 0.86  0.11, p ¼ 0.001).
11C-PK11195 signals corresponded well with
immunostained macrophages. Additionally, the
plaques of symptomatic patients exhibited relatively
lower CT Hounsﬁeld units, a feature associated
with lipid-laden and high-risk lesions. CT plaque
attenuation, however, did not correlate with
11C-PK11195 activity, suggesting that structural CT
and molecular PET information may be comple-
mentary approaches for plaque assessment. In com-
bination, high 11C-PK11195 signal with low CT
plaque attenuation achieved a high predictive value
>90% for identifying symptomatic carotid plaques in
this pilot study. An important next step is to deter-
mine whether elevated 11C-PK11195 signals will
predict carotid plaque progression and events in
asymptomatic patients. More importantly, the su-
periority of this agent compared with FDG will need
to be demonstrated, because FDG is widely avail-
able and enjoys signiﬁcant lead time in clinical
applications.
Pre-clinical advances. INTRAVASCULARNIRFIMAGING.
Noninvasive carotid plaque molecular imaging is
now established, but molecular imaging of the coronary
arteries, the primary source of acute MI, is in
its infancy. New approaches, particularly high-
resolution intravascular approaches, are actively under
development. Recent work demonstrates that intra-
vascular near-infrared ﬂuorescence (NIRF) imaging is
attractive for coronary artery molecular imaging. NIRF
imaging offers high resolution, good sensitivity, andmultiple imaging agent reporters, operationally utilizes
ﬂexible optical ﬁbers, and importantly, can enable
signal detection through blood. Using a specially
designed rotational imaging ﬁber housed in a con-
ventional intravascular ultrasound–style catheter, Jaffer
et al. (19) demonstrated the ability to capture
2-dimensional NIRF signals through ﬂowing blood,
without ﬂushing or vessel occlusion, in the aorta of
atherosclerotic rabbits, which have a similar size as
human coronary arteries. Rabbits injected 24 h before
intravascular imaging with ProSense VM110 (Perkin
Elmer, Hopkington, Massachusetts), a NIRF molec-
ular imaging agent that detects activated proteases
(cathepsins) resident within the arterial wall, showed
high NIRF inﬂammatory signals that colocalized with
intravascular ultrasound–veriﬁed plaques (Fig. 4).
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1334The authors also used the 2-dimensional NIRF system
to image coronary stent–induced inﬂammation,
revealing an edge-based inﬂammatory pattern in bare-
metal stents 7 days after implantation. Limitations of
that system included the lack of coregistered anatomic
information and semiquantitative readouts, limitations
that are addressed next.
NIRF–OPTICAL FREQUENCY DOMAIN IMAGING.
Standalone NIRF is semiquantitative due to lack
of precisely coregistered positional information.
Therefore, a new dual-modality NIRF–optical fre-
quency domain imaging (OFDI) molecular-
structural imaging catheter was recently developedFigure 4. Intravascular NIRF Imaging of Protease Inﬂammation in E
(A and B) Fluoroscopic and angiographic images (A, yellow dotted lin
B, solid yellow line: intravascular catheter tip position) positioned in th
longitudinal intravascular ultrasound (IVUS) demonstrates mild aortic pl
pullback aligned with images in A through C reveals NIRF protease activ
plot (bottom). (E) Superimposed longitudinal IVUS and NIRF fusion ima
(F and G) Longitudinal and (H and I) axial images of plaques P1 and P2.
by IVUS. Scale bars ¼ 10 mm. Reproduced, with permission, from Jafferfor simultaneous and quantitative NIRF molecular
imaging and anatomical OFDI, the high-speed
2nd-generation optical coherence tomography
technology (20). This clinical-type catheter system
enabled nanomolar NIRF detection with high-
resolution OFDI microstructural data (w7-mm
axial spatial resolution). Moreover, the availability of
positional information allowed distance correction of
the NIRF signal allowing quantiﬁcation of the NIRF
signal to luminal boundary. Intravascular experi-
ments in rabbits demonstrated the capability to
detect ﬁbrin deposition on stent struts and athero-
sclerotic plaque protease inﬂammatory activity.xperimental Atherosclerosis
es: high magniﬁcation inset of the radiopaque tip of the catheter;
e rabbit aorta, proximal to the iliac bifurcation. (C) Coregistered
aques P1 and P2. (D) Near-infrared ﬂuorescence (NIRF) catheter
ity at mild plaques (top) with a 1-dimensional angle-averaged NIRF
ges (NIRF color scale: yellow/white ¼ strong, red/black ¼ weak).
Arrowheads indicate areas of mild atherosclerotic plaque identiﬁed
et al. (19).
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1335Clinical translation of NIRF catheters is planned
within the next 1 to 2 years. This combined system is
positioned to provide the ﬁrst high-resolution maps
of coronary inﬂammation, especially as NIRF mo-
lecular imaging agents are becoming clinically
available (see the next section).
INDOCYANINE GREEN NIRF IMAGING OF LIPID-
RICH, INFLAMED PLAQUES. In addition to intra-
vascular NIRF catheters, clinically targeted NIRF
molecular imaging agents are needed to enable
coronary NIRF molecular imaging. Vinegoni et al.
(21) evaluated the use of the FDA-approved agent
indocyanine green (ICG) for NIRF plaque imaging
in atherosclerotic rabbits. ICG is a long-established
vascular NIRF imaging agent used for ophthalmo-
logic, cardiac, and hepatic blood ﬂow studies, and
ﬂuoresces in the near infrared. Twenty minutes after
intravenous ICG injection in rabbits, ICG localized
to lipid-laden, inﬂamed aortic plaques detected
by in vivo intravascular NIRF sensing. In vitro ex-
periments demonstrated ICG uptake was enhanced
by both lipid (acetylated LDL) and macrophages.
This observation was clinically supported by ICG
accumulation in macrophage- and lipid-rich zones
in freshly resected human CEA specimens incu-
bated with ICG. ICG combined with intravascularFigure 5. Elastin-Targeted MRI of Murine Atherosclerotic Plaque Re
(A) Gadolinium-labeled elastin-speciﬁc magnetic resonance contrast age
E–deﬁcient (apoE/) mouse brachiocephalic cross-sectional time-of-ﬂigh
contrast) with high-resolution contrast magnetic resonance imaging (MRI
158Gd-ESMA, and TOF/dynamic contrast (fusion) images. Scale bars ¼ 250NIRF catheter technology thus shows promise for
future human studies of high-risk coronary arterial
plaques. Challenges for NIRF imaging include the
lack of speciﬁc clinical tracers for atherosclerosis, but
recent developments in ﬂuorescence molecular im-
aging of clinical cancer patients (22) are expected to
produce a number of clinical NIRF agents in the
next 3 years.
MOLECULAR MRI OF ELASTIN AND PLAQUE
REMODELING. The extracellular matrix protein
elastin is an abundant component of evolving
atheroma related to underlying plaque burden. With
the introduction of a new low-molecular-weight
gadolinium-labeled elastin-speciﬁc magnetic reso-
nance contrast agent (158Gd-ESMA), elastin-rich
vascular regions can now be detected noninvasively
at high resolution and high signal-to-noise ratio
>10 (Fig. 5) (23). In apolipoprotein-E–deﬁcient
(apoE/) atherosclerotic mice, quantitative elastin
vessel-wall content assessed by 158Gd-ESMA
correlated with the time on a high-cholesterol diet,
and was diminished by 12 weeks of pravastatin
treatment. Furthermore, plaque cross-sectional
area and elastin content measured by histology
and immunoblotting exhibited a strongly positive
relationship with 158Gd-ESMA MRI contrastmodeling With 158Gd-ESMA
nt (158Gd-ESMA) chemical structure and formula. (B) Apolipoprotein-
t (TOF) angiography alignment (red box) comparing baseline (pre-
) (gadolinium-labeled diethylenetriamine penta acetic acid [Gd-DTPA]),
mm. Reproduced, with permission, from Makowski et al. (23).
Figure 6.
Mid-cardi
injection
baseline,
Three hou
angiotens
is signiﬁc
(26). Abbr
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1336enhancement (r2 > 0.7 for all comparators).
Another elastin-targeted MRI contrast agent being
pursued to noninvasively detect atherosclerotic pla-
que development and remodeling, BMS-753951,
also demonstrated promise to identify in-stent
restenosis in injured pig coronary arteries 4 weeks
after stent placement, with an excellent histology
correlation with plaque volume (r2 ¼ 0.86) (24). It
remains to be determined whether elastin molecular
MRI of plaque volume will provide a signiﬁcant
advance over coronary plaque volume imaging by
the latest generation of cardiac CT scanners.
MI and Thrombosis
Inﬂammation imaging in acute MI. Inﬂammation
is critical in healing an acute infarction by pro-
ducing a compact scar. However, excessive inﬂam-
mation may induce adverse myocardial remodeling
(left ventricular [LV] dilation). The ability to map
inﬂammation in human infarction could provide
new insights into the time course and topography of
MI-induced inﬂammation, and its attendant con-
sequences. In a proof-of-principle clinical study,
Alam et al. (25) imaged myocardial inﬂammation
via serial cardiac magnetic resonance (CMR) im-
aging of infarct macrophages, enabled by pre-
injection of ferumoxytol, a USPIO nanoparticle.
Ferumoxytol is FDA-approved for iron-deﬁciency
anemia in patients with chronic kidney disease,
but as a USPIO preparation, induces T2>T1
relaxation effects on MRI. A total of 16 patients
underwent USPIO-enhanced CMR imaging within
5 days after acute ST-segment elevation MI (25).
T2-weighted CMR imaging was performed atHuman Myocardial Angiotensin II Receptor PET/CT Imaging
ac PET/CT fusion images in a healthy volunteer obtained 1 h after
with the angiotensin II type I receptor ligand 11C-KR31173. (Left) At
11C-KR31173 signal localizes to the ventricular myocardium. (Right)
rs after administration of a single 40-mg oral (p.o.) dose of the
in receptor blocker olmesartan, myocardial 11C-KR31173 PET uptake
antly reduced. Reproduced, with permission, from Fukushima et al.
eviations as in Figure 1.baseline without agent, and then 24 and 48 h
following intravenous administration of 4 mg/kg
ferumoxytol. USPIOs induced T2-weighted signal
loss in the infarcted region, and to a lesser extent in
the noninfarcted remote myocardium. The overall
approach offers a new method to assess the in-
ﬂammatory response and LV remodeling in human
subjects, and could also be useful in the study of
myocarditis and cardiac transplant rejection. Future
efforts will likely focus on understanding post-MI
myocardial inﬂammatory levels and outcome (too
low / LV rupture, too high / LV dilation and
congestive heart failure). Molecular imaging should
help determine whether there is a sweet spot for
inﬂammation for optimal LV remodeling, and
whether post-MI therapies can be guided on the
basis of imaging.
ANGIOTENSIN RECEPTOR HYBRID PET/CT IMAGING
AFTER MI. Activation of the renin-angiotensin-
aldosterone system (RAAS) is an important
contributor to LV remodeling after MI. The novel
angiotensin II type 1 receptor (AT1R) PET ligand
11C-KR31173 was investigated in swine MI and
then in a ﬁrst-in-human evaluation in 4 healthy
volunteers (26). 11C-KR31173 was up-regulated 1 h
after injection in the myocardium of infarcted pigs
compared with healthy controls, with greatest ac-
tivity in the infarct zone (myocardial retention index
8.7%/min vs. 5.8%/min, p < 0.01). In humans,
11C-KR31173 also speciﬁcally localized to the
normal myocardium, but at lower levels than in the
infarcted and normal pig myocardium. Remarkably,
human subjects readministered 11C-KR31173
the following day 3 h after a single dose of an
angiotensin receptor blocker (40 mg olmesartan)
demonstrated decreased 11C-KR31173 PET activ-
ity (Fig. 6), although only 54% of receptors were
blocked, suggesting limited speciﬁcity of this agent.
Imaging of myocardial AT1R could have important
clinical implications, such as optimizing the dose
of angiotensin receptor blockers or motivating
additional therapies to suppress the RAAS axis.
If the current agent 11C-KR31173 also demon-
strates utility for congestive heart failure patients (as
opposed to just normal volunteers), future studies
could investigate whether up-regulated AT1R
expression reﬁnes prognosis beyond ejection frac-
tion, heart failure class, B-natriuretic peptide levels,
and other blood biomarkers. Comparative studies
are also required to determine whether AT1R im-
aging offers advantages beyond molecular imaging
of angiotensin-converting enzyme, a critical element
of the RAAS system that is upstream of AT1R and
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1337therefore may offer more sensitivity in reporting on
RAAS activation.
MI pre-clinical advances. After acute MI, why is the
risk of a recurrent event elevated in nonculprit ar-
teries? Patients who experience acute MI are at
elevated risk for future events, as high as 50%
during year 1 in some studies, but the mechanisms
underlying this phenomenon have not been estab-
lished. Dutta et al. (27) demonstrated that hyper-
cholesterolemic mice subjected to MI or stroke
developed larger atherosclerotic lesions with more
high-risk features, including macrophage inﬁltration
and inﬂammatory protease activity. In vivo assess-
ments were obtained using ﬂuorescence molecular
tomography with NIRF-targeted probes. Recruited
macrophages originated from migratory progenitor
cells traveling from the bone marrow to the spleen.
In the splenic tissue, progenitor cells up-regulated
monocyte/macrophage production via extramed-
ullary hematopoeisis. These macrophages then
exited the spleen, circulated, and honed to athero-
sclerotic plaques, accelerating atherosclerosis. En-
hanced bone marrow sympathetic nerve stimulation
was the driving force behind this process. Progenitor
cell release was reduced by beta-blocker therapy.
This important observation that MI itself acceler-
ates plaque growth and increases plaque inﬂamma-
tion sheds light on why extended dual antiplatelet
therapy confers a beneﬁt on nonculprit arteries
post-MI.
Thrombosis pre-clinical imaging advances. NEW
FIBRIN-TARGETED NIRF MOLECULAR IMAGING
AGENT. Approaches that detect speciﬁc thrombus-
associated molecules could more precisely deﬁne
thrombosis syndromes. Hara et al. (28) recently
developed a new NIRF agent targeted to ﬁbrin,
termed FTP11-Cy7. In murine deep vein throm-
bosis (DVT), FTP11-Cy7 rapidly accumulated in
thrombi detected by intravital confocal ﬂuorescence
microscopy and noninvasive ﬂuorescence molecular
tomography, and was blocked by competitive inhi-
bition of unlabeled probe. FTP11-Cy7 is likely
translatable for use in patients, because the peptide
backbone of this agent has been successfully tested
in phase II clinical MRI trials. In concert with
intravascular NIRF imaging (19,20), NIRF ﬁbrin
imaging is well positioned to investigate subclinical
plaque rupture and mechanisms of stent thrombosis
at very high resolution.
RELATIONSHIP BETWEEN VENOUS THROMBUS
INFLAMMATION AND RESOLUTION IN DVT. Similar
to MI, inﬂammation stabilizes acutely formed
DVT, but excessive inﬂammation may causebystander vein wall injury and increase the risk of
the post-thrombotic syndrome. Methods to image
inﬂammation in DVT could shed important light
on these outcomes. Using intravital confocal ﬂuo-
rescence microscopy, Ripplinger et al. (29) serially
assessed thrombus inﬂammation with ﬂuorescent
macrophage and MMP activity agents in chemical
DVT. The degree of macrophage and MMP
inﬂammation at day 4 predicted the amount of
thrombus reduction (area) at day 6 (p < 0.05). Thus
it is plausible that methods that quantify DVT
inﬂammation could provide prognostic information
into the risk of post-thrombotic syndrome, a com-
mon and morbid syndrome following DVT.
Stem cell therapies. EVOLUTION OF 2 DELIVERY
METHODS IN PATIENTS. Stem cell technologies
offer great potential for therapeutic myocardial
repair following acute MI, but in vivo mechanisms
governing stem cell targeting, retention, and thera-
peutic effects remain unknown. To provide new
insights into the comparative retention of 2
myocardial stem cell delivery strategies, Musialek
et al. (30) employed molecular imaging in acute MI
patients receiving autologous hematopoietic stem
cells shortly after MI. The authors compared
intracoronary distal stop-ﬂow injection through an
inﬂated over-the-wire (OTW) coronary angioplasty
balloon to a novel, nonocclusive, geometrically
optimized, side-hole cell delivery perfusion catheter
(PC). Thirty-four subjects were randomized in a 2:1
fashion to PC or OTW stem cell delivery within 14
days of acute anterior MI treated with percutaneous
coronary intervention (LV ejection fraction 22% to
44%). With the catheter tip positioned in the
recently placed left anterior descending coronary
artery stent, w4  106 CD34þ stem cells labeled
exogenously with 99mTc-exametazime were admin-
istered selectively to the injured coronary vascular
bed. At 1 h, single-photon emission computed to-
mography identiﬁed only 4.9% (OTW) and 5.1%
(PC) of the initial 99mTc-extametazime cell
population, with cells limited almost exclusively
to the (viable) peri-infarct zone as determined
by myocardial perfusion imaging. Despite a
nonsigniﬁcant difference in stem cell targeting be-
tween the 2 techniques, the nonocclusive PC group
experienced no injection intolerance or ventricular
arrhythmias, as opposed to the occlusive OTW
delivery approach that required minutes of coronary
ﬂow arrest. Compared with longer-term gene re-
porter cell-tracking strategies, exogenous labels are
most useful to assess the early success of stem cell
delivery because they may degrade or transfer out of
the cell over time.
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1338Vasculitis, Dissection, and Aneurysm
Large-vessel vasculitis. Inﬂammatory vasculitides
such as Takayasu arteritis and giant cell arteritis are
important causes of organ ischemia and infarction.
Mechanisms to understand the pathogenesis of
these diseases in patients are needed. Vascular
inﬂammation was evaluated in 78 consecutive
patients with suspected large-vessel vasculitis
using FDG PET/CT (31). After stratiﬁcation by
clinical diagnosis, 16 patients with steroid-naive
vasculitis exhibited greater FDG uptake in the
thoracic aorta and subclavian and carotid arteries
than in 18 vasculitis patients on steroid treatment.
Linear regression analysis revealed a positive corre-
lation between serum inﬂammatory biomarkers
(C-reactive protein, erythrocyte sedimentation rate)
and thoracic aorta FDG activity (b ¼ 0.018 to 0.02,
p < 0.05). In 27 Takayasu arteritis subjects with
active disease, FDG activity was similarly greater
than in patients with inactive disease or control
patients (maximum SUV: 2.7 vs. 1.9 vs. 1.8, p <lar Imaging of Inﬂammation in AAA
aps of T2-weighted magnetic resonance imaging (MRI) signal
red ¼ high) induced by local accumulation of ultrasmall super-
s of iron oxide (USPIO) in 3 patients with abdominal aortic aneurysms
ith enhanced periluminal T2 signal. (B) More diffuse, noncontiguous
ithin the intraluminal thrombus, but not involving the aortic wall. (C)
change with focal aortic T2 enhancement revealing USPIO accumu-
on within the AAA wall. (D and E) T2-weighted MRI images without
or maps for comparison demonstrating focal T2 signal loss at USPIO-
, with permission, from Richards et al. (34).0.001) (32). Furthermore, those patients with re-
lapsing disease on immunosuppressive treatment
had higher FDG activity compared with those with
treated stable disease (maximum SUV 2.6 vs. 1.9,
p < 0.001). Therefore, FDG inﬂammatory activity
detects large-vessel vasculitis activity, correlates with
treatment response, and may also facilitate earlier
detection of disease and monitoring of the response
to therapy.
Dissection. In a consecutive series of 37 patients
with spontaneous cervical artery dissection, FDG
PET demonstrated local inﬂammation at the
dissection site in >80% of patients (33). Interest-
ingly, about 20% of patients showed more extensive
generalized vessel-wall FDG uptake away from the
local dissection site, suggesting that an inﬂamma-
tory arteriopathy may have been present before the
dissection occurred. FDG PET/CT documented
diffuse inﬂammatory changes in more patients than
3-T contrast-enhanced MRI (24% vs. 14%). All
MRI-positive sites were also positive on FDG PET
(3 of 3), but not vice versa (only 4 of 7), suggesting
that FDG may be more sensitive than contrast-
enhanced MRI. Whether the degree of inﬂamma-
tion predicts arterial remodeling and aneurysm
formation, or atheroma formation, remains to be
determined.
Aneurysm. Can we better identify aneurysms that
might rapidly progress, dissect, or rupture?
ABDOMINAL AORTIC ANEURYSM. Using USPIO-
enhanced molecular 3-T MRI, Richards et al. (34)
investigated relationships between abdominal
aortic aneurysm (AAA) inﬂammation and subse-
quent aneurysm growth. Twenty-nine asymptom-
atic patients with AAA (range 4.0- to 6.6-cm
diameter) underwent intravenous administration of
the USPIO Sinerem (ferumoxtran, not yet FDA- or
European Medicines Agency–approved), followed
by T2-weighted imaging of AAA macrophages
(34). Although all subjects demonstrated peril-
uminal USPIO accumulation in a similar distribu-
tion to gadolinium enhancement, possibly due to
layering thrombus, some patients exhibited more
deeply located mural signal (Fig. 7). Despite similar
aneurysm sizes, patients with USPIO deposition in
the wall away from the periluminal thrombus
zones had a 3-fold higher aneurysm growth rate
(0.66 cm/year) compared with other patients (p ¼
0.02). If validated in larger and multicenter studies,
USPIO MRI could better identify patients suitable
for conservative therapy, or for early surgical ther-
apy, or for targeted enrollment in anti-inﬂammatory
clinical trials.
Figure 8. Clinical FDG PET Imaging of Inﬂammation in Aortic Stenosis
(A) CT-determined aortic valve calciﬁcation at differing aortic stenosis (AS)
severities. (B) Coregistered FDG PET/CT fusion demonstrates increased FDG
valve uptake for mild and moderate AS (arrows), that diminishes for heavily
calciﬁed severe AS. Reproduced, with permission, from Marincheva-Savcheva
et al. (36). Abbreviations as in Figure 1.
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1339CEREBRAL ANEURYSMS. Eleven patients with cere-
bral aneurysms were also imaged with USPIO to
determine the feasibility of intracranial aneurysm
inﬂammation detection in humans (35). Seventy-
two hours after ferumoxytol 5 mg/kg intravenous
injection, 78% of the aneurysms demonstrated
USPIO signal loss by MRI, and post-operative
analysis revealed macrophage and iron staining in
the resected aneurysm tissue. Both USPIO MRI
and FDG PET now provide opportunities to track
inﬂammation in aneurysms, and outcome and
comparison studies are anticipated in the next
several years.
Valvular Disease
Aortic stenosis. To address the relationship between
aortic valve inﬂammation and stenosis, FDG PET/
CT studies were retrospectively reviewed in 42
oncology patients with echocardiography-deﬁned
mild, moderate, or severe degenerative aortic steno-
sis (AS), and in an equal number of age-matched
controls (36). To minimize the bleed-through of
FDG signal from the adjacent myocardium and
aortic wall, signal analyses were performed with a 5-
mm3 voxel centered over the leaﬂet coaptation point.
Both mild and moderate AS patients had signiﬁ-
cantly elevated aortic valve FDG signal compared
with controls (TBR: 1.50 and 1.67, respectively;
TBR: 1.35 in controls; p # 0.01). Similar ﬁndings
were present when aortic valves were stratiﬁed by
mild or moderate CT calciﬁcation (Fig. 8). However,
in patients with severe calciﬁcation or severe AS,
FDG activity was similar to controls, suggesting
these conditions are at the end stage of the inﬂam-
matory process. Furthermore, in a subgroup of 19
patients with serial echocardiographic studies over 1
to 2 years, subjects with a high baseline FDG signal
showed AS progression in 82% of the group, whereas
subjects with lower FDG baseline signal showed
progression in only 22% of the group (p ¼ 0.04).
FDG PET may therefore be able to discriminate
patients at risk of more rapid progression of AS;
and excitingly, suggests the potential for early
anti-inﬂammatory therapies to slow the progression
of AS. Prospective studies are indicated.
A second study also demonstrated greater FDG
activity in the aortic valves of 121 patients with
increasing severity stenosis (37). NaF activity was
simultaneously assessed, with 91% of patients with
AS demonstrating NaF signal uptake. Intriguingly,
NaF correlated with the degree of AS more strongly
than FDG (r2 ¼ 0.54 vs. 0.218, both p < 0.001).
Correlation between FDG and NaF furthermorewas weak (r2 ¼ 0.174, p < 0.001), suggesting
different biological processes may be operative
during valvular stenosis. Although the SEAS
(Simvastatin and Ezetimibe in Aortic Stenosis) trial
of statin plus ezetimibe therapy to prevent AS
progression was negative, selection of patients with
active remodeling (via FDG and/or NaF) might
identify a population that could derive beneﬁt from
such a therapy, or potentially from other anti-
inﬂammatory or antimineralization therapies.
Device Complications and Infections
FDG PET identiﬁcation of device infections. Im-
plantable cardiovascular device infections are insid-
ious complications that can be difﬁcult to
deﬁnitively diagnose, and lead to considerable un-
certainty regarding whether explantation of the
implantable cardiovascular device is required. To
establish patterns of inﬂammation associated with
device infections, FDG PET imaging was utilized
in the following patients: 1) n ¼ 42 with a suspected
device infection; 2) n ¼ 12 with a recent device
implantation, but no evidence of infection; and
3) n ¼ 12 with an uncomplicated device implanta-
tion >6 months earlier (38). Nearly 75% of those
patients with suspected device infection had positive
FDG uptake, primarily at the device periphery, and
24 patients had their devices explanted with ex vivo
documentation of device infection. Six patients were
treated for a superﬁcial infection that resolved
without device removal, and 10 patients with no
FDG uptake were given antibiotic therapy without
relapse at >1 year. Subjects with recent device
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1340placement without known infection had mild up-
take on FDG PET/CT scans at the connector, but
devices implanted >6 months prior exhibited no
observed FDG signal. Thus, FDG can discriminate
post-implantation device inﬂammation from true
infection. If validated in larger studies, FDG PET
could vitally guide decisions between conservative
antibiotic therapy and device explanation.
Pre-clinical advances. MOLECULAR IMAGING OF
BACTERIAL ENDOCARDITIS. Early detection of
infective endocarditis to guide appropriate targeted
antibiotic and surgical intervention is often a sig-
niﬁcant challenge, but remains key to minimizing
subsequent complications such as paravalvular ab-
scess, septic emboli, and valve dehiscence. Panizzi
et al. (39) formulated 64Cu-DTPA-ProT, a novel
prothrombin analog for PET imaging that exploits
the natural bacterial host-defense mechanism of
coagulase-positive Staphylococcus aureus, a highly
destructive endovascular pathogen, by binding to
the staphylocoagulase enzyme. Coagulase-positive
Staphylococcus aureus aortic valve vegetations in
mice were highly detectable by 64Cu-DTPA-ProT
PET/CT imaging, but not coagulase-negative
strains. Importantly for potential future clinical
translation, there was no evidence of animal toxicity
or clotting disorders observed from the agent. Given
the clinical need for better diagnostic tools, targeted
bacterial agents such as 64Cu-DTPA-ProT are
likely to be highly translatable for diagnostic,
and possibly even theranostic (i.e., diagnostic þtherapeutic), infective endocarditis management.
Another exciting potential scenario is in the detec-
tion of culture-negative infective endocarditis, a
vexing clinical problem. Ideally, given that a number
of organisms can cause infective endocarditis, im-
aging agents that offer multiplexed detection are
likely to be more useful for clinical diagnostics.
Outlook
The rapid growth of cardiovascular molecular im-
aging has expanded our ability to understand disease
biology in vivo. Although FDG PET atheroscle-
rosis imaging remains at the forefront of this ﬁeld,
new clinical imaging approaches are expanding in
this area, as well as in cardiomyopathy, vasculitis,
valvular disease, aortic aneurysm and dissection, and
MI. Continued progress in human clinical cardio-
vascular molecular imaging studies is anticipated, as
recently witnessed over the period of this review
series. In particular, clinical molecular imaging trials
are now focusing on how molecular information can
improve risk stratiﬁcation beyond traditional struc-
tural imaging and routine clinical biomarkersda key
aspect that will deﬁne the long-term utility of car-
diovascular molecular imaging.
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